11th Jun 2026 16:45

LEI: 549300Q7EXQQH6KF7Z84
11 June 2026
RTW BIOTECH OPPORTUNITIES LTD
(the "Company")
Results of the Annual General Meeting ("AGM")
The Company is pleased to announce that, at the seventh AGM held at 14:00 BST today, 11 June 2026, each of the Resolutions was duly passed without amendment.
The details of each resolution are as follows:
ORDINARY RESOLUTIONS
Resolution 1
IT WAS RESOLVED to receive and consider the Audited Financial Statements, the Directors' report, and the auditor's report for the financial year ended 31 December 2025.
For | 147,624,501 votes |
Against | 689 votes |
Withheld | 349,382 votes |
Resolution 2
IT WAS RESOLVED to approve the Directors' remuneration for the financial year ended 31 December 2025 as provided in the Directors' report.
For | 146,866,008 votes |
Against | 173,755 votes |
Withheld | 934,809 votes |
Resolution 31
IT WAS RESOLVED to re-elect William Simpson as a Director of the Company.
For | 467,185,984 votes |
Against | 3,157,722 votes |
Withheld | 904,991 votes |
Resolution 41
IT WAS RESOLVED to re-elect Paul Le Page as a Director of the Company.
For | 469,816,955 votes |
Against | 1,081,611 votes |
Withheld | 350,131 votes |
Resolution 51
IT WAS RESOLVED to re-elect Bill Scott as a Director of the Company.
For | 469,261,671 votes |
Against | 1,636,018 votes |
Withheld | 351,008 votes |
Resolution 61
IT WAS RESOLVED to re-elect Baroness Nicola Blackwood as a Director of the Company.
For | 469,785,770 votes |
Against | 1,112,796 votes |
Withheld | 350,131 votes |
Resolution 7
IT WAS RESOLVED to re-elect Stephanie Sirota as a Director of the Company.
For | 145,703,036 votes |
Against | 1,269,679 votes |
Withheld | 1,001,857 votes |
Resolution 8
IT WAS RESOLVED to re-appoint KPMG Audit Limited and KPMG LLP as Auditor of the Company.
For | 147,584,005 votes |
Against | 41,698 votes |
Withheld | 348,869 votes |
Resolution 9
IT WAS RESOLVED to authorise the Board of Directors to determine the remuneration of the Auditor.
For | 147,496,974 votes |
Against | 103,097 votes |
Withheld | 374,501 votes |
As Special business
Resolution 10 IT WAS RESOLVED That the Company be and is hereby authorised, in accordance with section 315 of the Companies (Guernsey) Law, 2008, as amended (the "Companies Law"), subject to the Listing Rules made by the United Kingdom Financial Conduct Authority and all other applicable legislation and regulations, to make market acquisitions (within the meaning of section 316 of the Companies Law) of its own Ordinary Shares (as defined in the Company's Articles) which may be cancelled or held as treasury shares, provided that: i. the maximum number of Ordinary Shares authorised to be purchased under this authority shall be 48,514,750 Ordinary Shares (being 14.99 per cent. of the Ordinary Shares in issue as at the Latest Practicable Date, excluding any treasury shares); ii. the minimum price (exclusive of expenses) which may be paid for an Ordinary Share is US$0.01; iii. the maximum price (exclusive of expenses) which may be paid for an Ordinary Share shall be not more than an amount equal to the higher of (a) 5 per cent. above the average mid-market value of the Ordinary Shares on the regulated market where the repurchase is carried out for the five Business Days (as defined in the Company's Articles) prior to the day the purchase is made and (b) the higher of (i) the price of the last independent trade and (ii) the highest current independent bid price, in each case on the regulated market where the purchase is carried out; and
such authority is to expire on the date which is 15 months from the date of passing of this resolution or, if earlier, at the end of the Annual General Meeting of the Company to be held in 2027 (unless previously renewed, revoked or varied by the Company by ordinary resolution), save that the Company may make a contract to acquire Ordinary Shares under this authority before its expiry which will or may be executed wholly or partly after its expiration and the Company may make an acquisition of Ordinary Shares pursuant to such a contract. | ||||||||||||
| ||||||||||||
Special Resolution
Resolution 11 That the Directors be and are hereby authorised, to allot and issue or make offers or agreements to allot and issue, grant rights to subscribe or, or to convert any securities into, Ordinary Shares for cash up to the aggregate number of Ordinary Shares equal to 64,729,487 (being 20 per cent. of the Ordinary Shares in issue as at the Latest Practicable Date, excluding any treasury shares), and such authority to expire on the date which is 15 months from the date of the passing of this resolution or, if earlier, at the end of the Annual General Meeting of the Company to be held in 2027 (unless previously renewed, revoked or varied by the Company by a special resolution), save that the Company may, before such expiry, make an offer or agreement which would or might require Ordinary Shares to be allotted and issued after such expiry and the Directors may allot and issue Ordinary Shares (or sell from treasury) in pursuance of such an offer or agreement as if the authority conferred by this resolution had not expired.
Extraordinary Resolution
Resolution 12 That the Directors be and are hereby authorised, to allot and issue or make offers or agreements to allot and issue, grant rights to subscribe for, or to convert any securities into, Ordinary Shares for cash up to the aggregate number of Ordinary Shares equal to 64,729,487 (being an additional 20 per cent. of the Ordinary Shares in issue as at the Latest Practicable Date, excluding any treasury shares), and such authority to expire on the date which is 15 months from the date of the passing of this resolution or, if earlier, at the end of the Annual General Meeting of the Company to be held in 2027 (unless previously renewed, revoked or varied by the Company by a special resolution), save that the Company may, before such expiry, make an offer or agreement which would or might require Ordinary Shares to be allotted and issued after such expiry and the Directors may allot and issue Ordinary Shares in pursuance of such an offer or agreement as if the authority conferred by this resolution had not expired. This additional authority will only be utilised once the authority outlined within Resolution 11 has been exhausted and only if used in connection with an acquisition or a specified capital investment which is announced contemporaneously with the issue, or which has taken place in the preceding 12-month period and is disclosed in the announcement of the issue.
| ||||||||||||
Responses to investors' questions will be posted on the Company's website after the AGM.
1 The Company notes that the voting rights adjustments under Article 6 and Article 23 of the Company's Articles of Incorporation were used in respect of resolutions 3, 4, 5 and 6, but this did not affect the outcome of the shareholder vote.
|
*A vote withheld is not a vote in law and is therefore not counted towards the proportion of votes "for" or "against" the Resolution.
Enquiries:
RTW Investments, LP - Investment Manager Oliver Kenyon (Business & Corporate Development) Krisha McCune (Investor Relations)
| +44 (0)20 7959 6362 |
Deutsche Numis - Joint Corporate Broker Nathan Brown Duncan Monteith George Shiel
| +44 (0)20 7260 1000 |
About RTW Biotech Opportunities Ltd:
RTW Biotech Opportunities Ltd (LSE: RTW) is an investment fund focused on identifying transformative assets with high growth potential across the biopharmaceutical and medical technology sectors. Driven by a long-term approach to support innovative businesses, RTW Biotech Opportunities Ltd invests in companies developing next-generation therapies and technologies that can significantly improve patients' lives. RTW Biotech Opportunities Ltd is managed by RTW Investments, LP, a leading healthcare-focused entrepreneurial investment firm with deep scientific expertise and a strong track record of supporting companies developing life-changing therapies.
Visit the website at www.rtwbio.com for more information.
***********
The information in this announcement may include forward-looking statements, which are based on the current expectations and projections about future events, and in certain cases can be identified by the use of terms such as "may", "will", "should", "expect", "anticipate", "project", "estimate", "intend", "continue", "target", "believe" (or the negatives thereon) or other variations thereon or comparable terminology. These forward-looking statements are subject to risks, uncertainties and assumptions, and therefore the events in the forward-looking statements may not occur.
***********
Related Shares:
Rtw Biotech